P4783Treatment persistence of patients with atrial fibrillation on VKA or NOAC: Data from GLORIA-AF Phase III 1-year interim analysis

P4783Treatment persistence of patients with atrial fibrillation on VKA or NOAC: Data from GLORIA-AF Phase III 1-year interim analysis

Abstract Background Oral anticoagulation (OAC) persistence is important for optimizing stroke prevention in patients with atrial fibrillation (AF); non-vitamin K oral anticoagulants (NOACs) generally show better persistence than vitamin K antagonists (VKAs), while the impact of dosing regimens remai...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European heart journal 2019-10, Vol.40 (Supplement_1)
Hauptverfasser: Lip, G Y H, Diener, H.-C, Dubner, S J, Halperin, J L, Rothman, K J, Ma, C.-S, Lu, S, Paquette, M, Riou Franca, L, Zint, K, Teutsch, C, Huisman, M V
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue Supplement_1
container_start_page
container_title European heart journal
container_volume 40
creator Lip, G Y H
Diener, H.-C
Dubner, S J
Halperin, J L
Rothman, K J
Ma, C.-S
Lu, S
Paquette, M
Riou Franca, L
Zint, K
Teutsch, C
Huisman, M V
description Abstract Background Oral anticoagulation (OAC) persistence is important for optimizing stroke prevention in patients with atrial fibrillation (AF); non-vitamin K oral anticoagulants (NOACs) generally show better persistence than vitamin K antagonists (VKAs), while the impact of dosing regimens remains unclear. We compared treatment persistence of NOACs and VKAs, and of NOAC dosing regimens in the prospective GLORIA-AF registry program. Methods Patients newly diagnosed with AF were enrolled in Phase III of GLORIA-AF (2014–2016) from 4 geographical regions (North America [NA], Europe, Asia and Latin America). Treatment persistence after 1 year for i) NOAC (dabigatran, rivaroxaban, apixaban, edoxaban) vs VKA, and ii) twice daily (bid, dabigatran, apixaban) vs once daily (od; rivaroxaban, edoxaban) NOAC treatment was analysed using multivariable Cox analysis; propensity score trimming was used to reduce bias due to unmeasured confounders. Missing data was handled by multiple imputation. Results Overall, 21,592 patients were enrolled (4970 [23%] patients on VKAs, 12,797 [59%] on NOACs, 2391 [11%] on antiplatelets, and 1426 [6.6%] received no therapy; 8 [0.04%] received other treatment). After trimming, 11,935 and 4484 patients treated with NOACs and VKAs, respectively, were compared. NOACs had better treatment persistence than VKAs (discontinuation hazard ratio [HR]=0.75, 95% confidence interval [CI] 0.69–0.81). Other relevant associations were decreased OAC persistence for symptomatic AF, NA and Asia regions (Table). There was no difference in treatment persistence for patients on a bid (N=7842) vs od (N=4098) NOAC (discontinuation HR=0.94, 95% CI 0.86–1.02). Conclusion In this 1-year interim analysis of GLORIA-AF Phase III, treatment persistence was improved with NOACs vs VKAs, whereas for NOACs, dosing regimen (bid vs od) had no impact on treatment persistence. Acknowledgement/Funding The GLORIA-AF Registry program was funded by Boehringer-Ingelheim
doi_str_mv 10.1093/eurheartj/ehz745.1159
format Article
fullrecord <record><control><sourceid>oup_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1093_eurheartj_ehz745_1159</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/eurheartj/ehz745.1159</oup_id><sourcerecordid>10.1093/eurheartj/ehz745.1159</sourcerecordid><originalsourceid>FETCH-LOGICAL-c879-7bf167a6ce13454b103426635992faf802f19ce8ac0d0dc6a36d3a391a54535d3</originalsourceid><addsrcrecordid>eNqNkFFLwzAQx4MoOKcfQbgv0C1pmrTxrUw3i8MNGeJbubUJ7ejakmTIfPd72zHxWTg4uON39-dHyD2jE0YVn-qDrTRav5vq6iuOxIQxoS7IiIkwDJSMxCUZUaZEIGXycU1unNtRShPJ5Ih8r6M44Rur0e9166HX1tXO67bQ0Bno0dfD2MFn7StAb2tswNRbWzfNsOpaGOr9JYXOwusqnT3AI3oEY7s9LJartywN0jmsK3QasiwDFhyHpFC3Xtt6D9hicxz-3ZIrg43Td799TDbzp83sOViuFtksXQZFEqsg3homY5SFZjwS0ZZRHoVScqFUaNAkNDRMFTrBgpa0LCRyWXLkiqGIBBclHxNxPlvYzjmrTd4PKdAec0bzk8r8T2V-VpmfVA4cPXPdof8n8gNYTXs-</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>P4783Treatment persistence of patients with atrial fibrillation on VKA or NOAC: Data from GLORIA-AF Phase III 1-year interim analysis</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>Alma/SFX Local Collection</source><creator>Lip, G Y H ; Diener, H.-C ; Dubner, S J ; Halperin, J L ; Rothman, K J ; Ma, C.-S ; Lu, S ; Paquette, M ; Riou Franca, L ; Zint, K ; Teutsch, C ; Huisman, M V</creator><creatorcontrib>Lip, G Y H ; Diener, H.-C ; Dubner, S J ; Halperin, J L ; Rothman, K J ; Ma, C.-S ; Lu, S ; Paquette, M ; Riou Franca, L ; Zint, K ; Teutsch, C ; Huisman, M V</creatorcontrib><description>Abstract Background Oral anticoagulation (OAC) persistence is important for optimizing stroke prevention in patients with atrial fibrillation (AF); non-vitamin K oral anticoagulants (NOACs) generally show better persistence than vitamin K antagonists (VKAs), while the impact of dosing regimens remains unclear. We compared treatment persistence of NOACs and VKAs, and of NOAC dosing regimens in the prospective GLORIA-AF registry program. Methods Patients newly diagnosed with AF were enrolled in Phase III of GLORIA-AF (2014–2016) from 4 geographical regions (North America [NA], Europe, Asia and Latin America). Treatment persistence after 1 year for i) NOAC (dabigatran, rivaroxaban, apixaban, edoxaban) vs VKA, and ii) twice daily (bid, dabigatran, apixaban) vs once daily (od; rivaroxaban, edoxaban) NOAC treatment was analysed using multivariable Cox analysis; propensity score trimming was used to reduce bias due to unmeasured confounders. Missing data was handled by multiple imputation. Results Overall, 21,592 patients were enrolled (4970 [23%] patients on VKAs, 12,797 [59%] on NOACs, 2391 [11%] on antiplatelets, and 1426 [6.6%] received no therapy; 8 [0.04%] received other treatment). After trimming, 11,935 and 4484 patients treated with NOACs and VKAs, respectively, were compared. NOACs had better treatment persistence than VKAs (discontinuation hazard ratio [HR]=0.75, 95% confidence interval [CI] 0.69–0.81). Other relevant associations were decreased OAC persistence for symptomatic AF, NA and Asia regions (Table). There was no difference in treatment persistence for patients on a bid (N=7842) vs od (N=4098) NOAC (discontinuation HR=0.94, 95% CI 0.86–1.02). Conclusion In this 1-year interim analysis of GLORIA-AF Phase III, treatment persistence was improved with NOACs vs VKAs, whereas for NOACs, dosing regimen (bid vs od) had no impact on treatment persistence. Acknowledgement/Funding The GLORIA-AF Registry program was funded by Boehringer-Ingelheim</description><identifier>ISSN: 0195-668X</identifier><identifier>EISSN: 1522-9645</identifier><identifier>DOI: 10.1093/eurheartj/ehz745.1159</identifier><language>eng</language><publisher>Oxford University Press</publisher><ispartof>European heart journal, 2019-10, Vol.40 (Supplement_1)</ispartof><rights>Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2019. For permissions, please email: journals.permissions@oup.com. 2019</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,1584,27924,27925</link.rule.ids></links><search><creatorcontrib>Lip, G Y H</creatorcontrib><creatorcontrib>Diener, H.-C</creatorcontrib><creatorcontrib>Dubner, S J</creatorcontrib><creatorcontrib>Halperin, J L</creatorcontrib><creatorcontrib>Rothman, K J</creatorcontrib><creatorcontrib>Ma, C.-S</creatorcontrib><creatorcontrib>Lu, S</creatorcontrib><creatorcontrib>Paquette, M</creatorcontrib><creatorcontrib>Riou Franca, L</creatorcontrib><creatorcontrib>Zint, K</creatorcontrib><creatorcontrib>Teutsch, C</creatorcontrib><creatorcontrib>Huisman, M V</creatorcontrib><title>P4783Treatment persistence of patients with atrial fibrillation on VKA or NOAC: Data from GLORIA-AF Phase III 1-year interim analysis</title><title>European heart journal</title><description>Abstract Background Oral anticoagulation (OAC) persistence is important for optimizing stroke prevention in patients with atrial fibrillation (AF); non-vitamin K oral anticoagulants (NOACs) generally show better persistence than vitamin K antagonists (VKAs), while the impact of dosing regimens remains unclear. We compared treatment persistence of NOACs and VKAs, and of NOAC dosing regimens in the prospective GLORIA-AF registry program. Methods Patients newly diagnosed with AF were enrolled in Phase III of GLORIA-AF (2014–2016) from 4 geographical regions (North America [NA], Europe, Asia and Latin America). Treatment persistence after 1 year for i) NOAC (dabigatran, rivaroxaban, apixaban, edoxaban) vs VKA, and ii) twice daily (bid, dabigatran, apixaban) vs once daily (od; rivaroxaban, edoxaban) NOAC treatment was analysed using multivariable Cox analysis; propensity score trimming was used to reduce bias due to unmeasured confounders. Missing data was handled by multiple imputation. Results Overall, 21,592 patients were enrolled (4970 [23%] patients on VKAs, 12,797 [59%] on NOACs, 2391 [11%] on antiplatelets, and 1426 [6.6%] received no therapy; 8 [0.04%] received other treatment). After trimming, 11,935 and 4484 patients treated with NOACs and VKAs, respectively, were compared. NOACs had better treatment persistence than VKAs (discontinuation hazard ratio [HR]=0.75, 95% confidence interval [CI] 0.69–0.81). Other relevant associations were decreased OAC persistence for symptomatic AF, NA and Asia regions (Table). There was no difference in treatment persistence for patients on a bid (N=7842) vs od (N=4098) NOAC (discontinuation HR=0.94, 95% CI 0.86–1.02). Conclusion In this 1-year interim analysis of GLORIA-AF Phase III, treatment persistence was improved with NOACs vs VKAs, whereas for NOACs, dosing regimen (bid vs od) had no impact on treatment persistence. Acknowledgement/Funding The GLORIA-AF Registry program was funded by Boehringer-Ingelheim</description><issn>0195-668X</issn><issn>1522-9645</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNqNkFFLwzAQx4MoOKcfQbgv0C1pmrTxrUw3i8MNGeJbubUJ7ejakmTIfPd72zHxWTg4uON39-dHyD2jE0YVn-qDrTRav5vq6iuOxIQxoS7IiIkwDJSMxCUZUaZEIGXycU1unNtRShPJ5Ih8r6M44Rur0e9166HX1tXO67bQ0Bno0dfD2MFn7StAb2tswNRbWzfNsOpaGOr9JYXOwusqnT3AI3oEY7s9LJartywN0jmsK3QasiwDFhyHpFC3Xtt6D9hicxz-3ZIrg43Td799TDbzp83sOViuFtksXQZFEqsg3homY5SFZjwS0ZZRHoVScqFUaNAkNDRMFTrBgpa0LCRyWXLkiqGIBBclHxNxPlvYzjmrTd4PKdAec0bzk8r8T2V-VpmfVA4cPXPdof8n8gNYTXs-</recordid><startdate>20191001</startdate><enddate>20191001</enddate><creator>Lip, G Y H</creator><creator>Diener, H.-C</creator><creator>Dubner, S J</creator><creator>Halperin, J L</creator><creator>Rothman, K J</creator><creator>Ma, C.-S</creator><creator>Lu, S</creator><creator>Paquette, M</creator><creator>Riou Franca, L</creator><creator>Zint, K</creator><creator>Teutsch, C</creator><creator>Huisman, M V</creator><general>Oxford University Press</general><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20191001</creationdate><title>P4783Treatment persistence of patients with atrial fibrillation on VKA or NOAC: Data from GLORIA-AF Phase III 1-year interim analysis</title><author>Lip, G Y H ; Diener, H.-C ; Dubner, S J ; Halperin, J L ; Rothman, K J ; Ma, C.-S ; Lu, S ; Paquette, M ; Riou Franca, L ; Zint, K ; Teutsch, C ; Huisman, M V</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c879-7bf167a6ce13454b103426635992faf802f19ce8ac0d0dc6a36d3a391a54535d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lip, G Y H</creatorcontrib><creatorcontrib>Diener, H.-C</creatorcontrib><creatorcontrib>Dubner, S J</creatorcontrib><creatorcontrib>Halperin, J L</creatorcontrib><creatorcontrib>Rothman, K J</creatorcontrib><creatorcontrib>Ma, C.-S</creatorcontrib><creatorcontrib>Lu, S</creatorcontrib><creatorcontrib>Paquette, M</creatorcontrib><creatorcontrib>Riou Franca, L</creatorcontrib><creatorcontrib>Zint, K</creatorcontrib><creatorcontrib>Teutsch, C</creatorcontrib><creatorcontrib>Huisman, M V</creatorcontrib><collection>CrossRef</collection><jtitle>European heart journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lip, G Y H</au><au>Diener, H.-C</au><au>Dubner, S J</au><au>Halperin, J L</au><au>Rothman, K J</au><au>Ma, C.-S</au><au>Lu, S</au><au>Paquette, M</au><au>Riou Franca, L</au><au>Zint, K</au><au>Teutsch, C</au><au>Huisman, M V</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>P4783Treatment persistence of patients with atrial fibrillation on VKA or NOAC: Data from GLORIA-AF Phase III 1-year interim analysis</atitle><jtitle>European heart journal</jtitle><date>2019-10-01</date><risdate>2019</risdate><volume>40</volume><issue>Supplement_1</issue><issn>0195-668X</issn><eissn>1522-9645</eissn><abstract>Abstract Background Oral anticoagulation (OAC) persistence is important for optimizing stroke prevention in patients with atrial fibrillation (AF); non-vitamin K oral anticoagulants (NOACs) generally show better persistence than vitamin K antagonists (VKAs), while the impact of dosing regimens remains unclear. We compared treatment persistence of NOACs and VKAs, and of NOAC dosing regimens in the prospective GLORIA-AF registry program. Methods Patients newly diagnosed with AF were enrolled in Phase III of GLORIA-AF (2014–2016) from 4 geographical regions (North America [NA], Europe, Asia and Latin America). Treatment persistence after 1 year for i) NOAC (dabigatran, rivaroxaban, apixaban, edoxaban) vs VKA, and ii) twice daily (bid, dabigatran, apixaban) vs once daily (od; rivaroxaban, edoxaban) NOAC treatment was analysed using multivariable Cox analysis; propensity score trimming was used to reduce bias due to unmeasured confounders. Missing data was handled by multiple imputation. Results Overall, 21,592 patients were enrolled (4970 [23%] patients on VKAs, 12,797 [59%] on NOACs, 2391 [11%] on antiplatelets, and 1426 [6.6%] received no therapy; 8 [0.04%] received other treatment). After trimming, 11,935 and 4484 patients treated with NOACs and VKAs, respectively, were compared. NOACs had better treatment persistence than VKAs (discontinuation hazard ratio [HR]=0.75, 95% confidence interval [CI] 0.69–0.81). Other relevant associations were decreased OAC persistence for symptomatic AF, NA and Asia regions (Table). There was no difference in treatment persistence for patients on a bid (N=7842) vs od (N=4098) NOAC (discontinuation HR=0.94, 95% CI 0.86–1.02). Conclusion In this 1-year interim analysis of GLORIA-AF Phase III, treatment persistence was improved with NOACs vs VKAs, whereas for NOACs, dosing regimen (bid vs od) had no impact on treatment persistence. Acknowledgement/Funding The GLORIA-AF Registry program was funded by Boehringer-Ingelheim</abstract><pub>Oxford University Press</pub><doi>10.1093/eurheartj/ehz745.1159</doi></addata></record>
fulltext fulltext
identifier ISSN: 0195-668X
ispartof European heart journal, 2019-10, Vol.40 (Supplement_1)
issn 0195-668X
1522-9645
language eng
recordid cdi_crossref_primary_10_1093_eurheartj_ehz745_1159
source Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Oxford University Press Journals All Titles (1996-Current); Alma/SFX Local Collection
title P4783Treatment persistence of patients with atrial fibrillation on VKA or NOAC: Data from GLORIA-AF Phase III 1-year interim analysis
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T01%3A05%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-oup_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=P4783Treatment%20persistence%20of%20patients%20with%20atrial%20fibrillation%20on%20VKA%20or%20NOAC:%20Data%20from%20GLORIA-AF%20Phase%20III%201-year%20interim%20analysis&rft.jtitle=European%20heart%20journal&rft.au=Lip,%20G%20Y%20H&rft.date=2019-10-01&rft.volume=40&rft.issue=Supplement_1&rft.issn=0195-668X&rft.eissn=1522-9645&rft_id=info:doi/10.1093/eurheartj/ehz745.1159&rft_dat=%3Coup_cross%3E10.1093/eurheartj/ehz745.1159%3C/oup_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_oup_id=10.1093/eurheartj/ehz745.1159&rfr_iscdi=true